Telix Pharmaceuticals Limited
TLX
$9.36
-$0.07-0.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.17% | 57.02% | 54.60% | 64.37% | 75.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.17% | 57.02% | 54.60% | 64.37% | 75.57% |
| Cost of Revenue | 87.89% | 78.79% | 49.86% | 60.30% | 72.47% |
| Gross Profit | 39.39% | 43.66% | 57.68% | 67.01% | 77.59% |
| SG&A Expenses | 56.59% | 64.72% | 66.53% | 71.45% | 75.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 181.70% | 187.19% | 2,826.46% | 589.17% | 258.26% |
| Total Operating Expenses | 67.94% | 75.95% | 56.40% | 63.05% | 69.33% |
| Operating Income | -41.13% | -50.29% | 38.87% | 78.83% | 180.50% |
| Income Before Tax | -71.58% | -27.47% | 2,053.72% | 378.69% | 220.71% |
| Income Tax Expenses | -460.44% | -165.86% | 390.95% | 29.10% | -89.72% |
| Earnings from Continuing Operations | -65.50% | -4.07% | 971.69% | 329.12% | 200.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.50% | -4.07% | 971.69% | 329.12% | 200.69% |
| EBIT | -41.13% | -50.29% | 38.87% | 78.83% | 180.50% |
| EBITDA | -26.47% | -42.60% | 35.84% | 70.24% | 147.12% |
| EPS Basic | -62.14% | -24.84% | 856.52% | 294.05% | 186.49% |
| Normalized Basic EPS | -33.68% | -47.52% | 70.12% | 145.52% | 601.20% |
| EPS Diluted | -63.35% | -26.25% | 934.15% | 285.84% | 184.22% |
| Normalized Diluted EPS | -35.80% | -49.56% | 65.30% | 140.07% | 583.13% |
| Average Basic Shares Outstanding | -17.24% | 29.69% | 29.35% | 28.96% | 28.56% |
| Average Diluted Shares Outstanding | -17.81% | 31.69% | 32.76% | 32.72% | 32.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |